Linrodostat
 | |
| Clinical data | |
|---|---|
| Other names | BMS-986205; ONO 7701 |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C24H24ClFN2O |
| Molar mass | 410.92 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Linrodostat (development code BMS-986205) is an experimental drug being studied for its immunomodulating and antineoplastic activities.[1]
Linrodostat is an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1).[2][3]
Linrodostat has entered clinical trials for a variety of cancer types including bladder cancer, head and neck cancer, endometrial cancer, gastric cancer, malignant melanoma, liver cancer, non-small cell lung cancer, and solid tumors.[4]
References
[edit]- ^ "Linrodostat". NCI Drug Dictionary. National Cancer Institute.
- ^ Balog A, Lin TA, Maley D, Gullo-Brown J, Kandoussi EH, Zeng J, Hunt JT (March 2021). "Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor". Molecular Cancer Therapeutics. 20 (3): 467–476. doi:10.1158/1535-7163.MCT-20-0251. PMID 33298590. S2CID 228087398.
- ^ "IDO Inhibitor Development Shows Fresh Signs of Life Across Tumor Types". onclive.com. October 31, 2019.
- ^ "Linrodostat". Adis Insight. Springer Nature Switzerland AG.
External links
[edit]- Fraunhoffer KJ, Delmonte AJ, Beutner GL, Bultman MS, Camacho K, Cohen B, et al. (2019). "Rapid Development of a Commercial Process for Linrodostat, an Indoleamine 2,3-Dioxygenase (IDO) Inhibitor". Organic Process Research & Development. 23 (11): 2482–2498. doi:10.1021/acs.oprd.9b00359. S2CID 208690975.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |